250 related articles for article (PubMed ID: 11468181)
1. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.
Mitsiades CS; Treon SP; Mitsiades N; Shima Y; Richardson P; Schlossman R; Hideshima T; Anderson KC
Blood; 2001 Aug; 98(3):795-804. PubMed ID: 11468181
[TBL] [Abstract][Full Text] [Related]
2. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Expert Opin Investig Drugs; 2001 Aug; 10(8):1521-30. PubMed ID: 11772267
[TBL] [Abstract][Full Text] [Related]
3. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
Mitsiades CS; Mitsiades N; Poulaki V; Schlossman R; Akiyama M; Chauhan D; Hideshima T; Treon SP; Munshi NC; Richardson PG; Anderson KC
Oncogene; 2002 Aug; 21(37):5673-83. PubMed ID: 12173037
[TBL] [Abstract][Full Text] [Related]
4. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
[TBL] [Abstract][Full Text] [Related]
5. Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Chawla-Sarkar M; Bauer JA; Lupica JA; Morrison BH; Tang Z; Oates RK; Almasan A; DiDonato JA; Borden EC; Lindner DJ
J Biol Chem; 2003 Oct; 278(41):39461-9. PubMed ID: 12881518
[TBL] [Abstract][Full Text] [Related]
6. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
8. TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines.
Yoshida S; Narita T; Koshida S; Ohta S; Takeuchi Y
Pediatr Res; 2003 Nov; 54(5):709-17. PubMed ID: 12904602
[TBL] [Abstract][Full Text] [Related]
9. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
Bouralexis S; Findlay DM; Atkins GJ; Labrinidis A; Hay S; Evdokiou A
Br J Cancer; 2003 Jul; 89(1):206-14. PubMed ID: 12838325
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells.
Hermisson M; Weller M
Cell Death Differ; 2003 Sep; 10(9):1078-89. PubMed ID: 12934082
[TBL] [Abstract][Full Text] [Related]
11. Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.
Thai le M; Labrinidis A; Hay S; Liapis V; Bouralexis S; Welldon K; Coventry BJ; Findlay DM; Evdokiou A
Cancer Res; 2006 May; 66(10):5363-70. PubMed ID: 16707463
[TBL] [Abstract][Full Text] [Related]
12. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Chawla-Sarkar M; Leaman DW; Jacobs BS; Borden EC
J Immunol; 2002 Jul; 169(2):847-55. PubMed ID: 12097388
[TBL] [Abstract][Full Text] [Related]
13. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Fong S; Totpal K; Lawrence D; Zheng Z; Ross J; Koeppen H; Schwall R; Ashkenazi A
Cancer Res; 2004 Jul; 64(14):4900-5. PubMed ID: 15256461
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
Shipman CM; Croucher PI
Cancer Res; 2003 Mar; 63(5):912-6. PubMed ID: 12615702
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.
Evdokiou A; Bouralexis S; Atkins GJ; Chai F; Hay S; Clayer M; Findlay DM
Int J Cancer; 2002 Jun; 99(4):491-504. PubMed ID: 11992538
[TBL] [Abstract][Full Text] [Related]
16. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Blood; 2002 Mar; 99(6):2162-71. PubMed ID: 11877293
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines.
Matsuda T; Almasan A; Tomita M; Uchihara JN; Masuda M; Ohshiro K; Takasu N; Yagita H; Ohta T; Mori N
J Virol; 2005 Feb; 79(3):1367-78. PubMed ID: 15650163
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells.
Wu XX; Kakehi Y; Mizutani Y; Nishiyama H; Kamoto T; Megumi Y; Ito N; Ogawa O
Int J Cancer; 2003 Apr; 104(4):409-17. PubMed ID: 12584736
[TBL] [Abstract][Full Text] [Related]
19. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
20. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Richardson PG; Hideshima T; Munshi N; Treon SP; Anderson KC
Blood; 2002 Jun; 99(11):4079-86. PubMed ID: 12010810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
